To examine the mechanisms by which endothelin (ET) regulates the Na/H antiporter isoform, NHE-3, OKP 
Introduction
The endothelins (ET) 1 are potent vasoconstrictors that function as paracrine and autocrine factors. Three isoforms, ET-1, -2, and -3, interact with two receptors, ET A and ET B . ET A receptors bind ET-1 and ET-2 with high affinity, whereas ET-3 binds with low affinity; ET B receptors bind ET-1, -2, and -3 with similar high affinities (1, 2) . In addition to causing vasoconstriction, the endothelins may also increase blood pressure through renal sodium retention. At low concentrations, ET-1 increases proximal tubule sodium and volume absorption, whereas at high concentrations these processes are inhibited (3) . Proximal tubule transcellular NaCl absorption is mediated by an apical membrane Na/H antiporter, encoded predominantly by the isoform NHE-3 (4-6). ET-1 applied to renal cortical slices or directly to brush border membrane vesicles stimulates apical membrane Na/H antiporter activity (7, 8) .
OKP cells express NHE-3 and have been useful for the study of NHE-3 regulation (9) . In the present studies, we overexpressed ET A and ET B receptors in OKP cells and examined the regulation of NHE-3 by ET-1. The results demonstrate that binding of ET-1 to the ET B receptor activates Na/H antiporter activity. This effect is mediated in part through increases in cell [Ca Cell culture. OKP cells were passaged in high glucose (450 mg/dl) DME supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (100 g/ml). For study, cells were grown in low glucose (100 mg/dl) DME. When confluent, cells were rendered quiescent for 48 h before study by the removal of serum. To overexpress human ET A and ET B receptors, cells were transfected with plasmids pMEhET A and pMEhET B , which contained the respective receptor cDNAs driven by an SR ␣ promoter (10, 11) . Each plasmid was cotransfected with pSV2-neo using calcium phosphate coprecipitation. Neomycinresistant cells were selected by growth in 400 g/ml G-418 and maintained in 200 g/ml G-418. Clonal cell lines were isolated by limiting dilution and screened by Northern blot for maximal expression. For experimentation, G-418 was removed at the time of splitting, 5-7 d before study.
To measure ET-1 binding, cells were grown to confluence in 12-well plates, rendered quiescent, and incubated in medium containing 0.3% BSA, 20 pM 125 I-ET-1, and varying amounts of cold ET-1 for 1 h at 37 Њ C. Incubation medium was then aspirated, the cells were washed twice with cold PBS, and the cells were harvested in 1 N NaOH.
Measurement of intracellular pH and Na/H antiporter activity. Continuous measurement of cytoplasmic pH (pHi) was accomplished in cells grown on coverslips using the intracellularly trapped pH-sensitive dye BCECF, as previously described (12) . pHi was estimated from the ratio of fluorescence with excitation wavelengths of 500 and 450 nm and emission wavelength 530 nm (SLM 8000C, Rochester, NY). Calibration of the BCECF excitation ratio was accomplished using the nigericin technique as described (12) .
Na/H antiporter activity was assayed as the initial rate of Nadependent pHi recovery from an acid load in the absence of CO 2 / HCO 3 . For this assay, Na-containing solution was (in mM): 130 Na, 5.0 K, 1.1 Ca, 1.5 Mg, 140.2 Cl, and 30 Hepes. In Na-free solutions, Na was replaced with choline. All solutions were adjusted to pH 7.4 with N -methyl-d -glucammonium hydroxide at 37 Њ C. Cells were first bathed in Na-containing solution, and baseline pHi was measured. The bath was then changed to Na-free solution containing 13 M nigericin ϫ 4 min, which caused pHi to decrease to ‫ف‬ 6.4-6.6. Nigericin was then removed, and the cells were washed with 1% (wt/vol) dialyzed BSA in Na-free solution for 2 min. Cells were then bathed in the Na-free perfusate for 30 s. Subsequent replacement with Na-containing solution caused a rapid pHi recovery that was due to the Na/H antiporter (13) . The initial rate of this Na-dependent pHi change (dpHi/dt) was calculated by drawing a tangent to the initial deflection. In all studies, control and experimental cells were from the same passage and were assayed on the same day. pHi at which Na was added was not different between groups. Exposure to ET-1 was begun at the time of loading with BCECF and was maintained throughout the duration of the assay ( ‫ف‬ 35 min) unless otherwise stated. All control cells were exposed to appropriate vehicle.
To calculate buffer capacity, cells were pulsed with 10 mM NH 4 Cl in the Na-free perfusate, and buffer capacity was calculated at the trough pHi, as previously described (14) . 10 Ϫ 8 M ET-1 had no effect on buffer capacity in ET B 6 cells ( ␤ ϭ 40.4 Ϯ 1.9 vs 42.2 Ϯ 2.4 mM/liter и pH U, ET-1 vs control, NS). Na/H antiporter activity is therefore expressed as dpHi/dt. cAMP radioimmunoassay. For measurement of cAMP production, cells were rinsed twice with PBS and incubated in 1 ml of serumfree medium at 37 Њ C in 5% CO 2 for 1 h with or without ET-1 and with 10 Ϫ 7 M PTH and 2 mM 3-isobutyl-1-methylxanthine. Control wells were exposed to appropriate vehicles. After incubation, cell protein was precipitated by the addition of 100 l of 100% TCA to each well. After 20 min at room temperature, the supernatant was carefully harvested, extracted three times with water-saturated ether, and used to measure cAMP concentration by radioimmunoassay. Protein content per well was determined after solubilization of the precipitate with 1 N NaOH, as described by Lowry et al. (15) .
Cell calcium. 
Results

Binding of ET-1 to ET B receptors activates NHE-3. In initial studies, 10
Ϫ8 M ET-1 caused a 16% increase in Na/H antiporter activity in OKP cells (dpHi/dt ϭ 0.94Ϯ0.04 pH U/min, control vs 1.09Ϯ0.04 pH U/min, ET-1; n ϭ 13, control; n ϭ 11, ET-1; P Ͻ 0.01). Whereas this result suggested that endothelin could activate NHE-3, this magnitude of regulation would likely be difficult to consistently reproduce and thus to study.
To examine whether increasing endothelin receptor abundance would increase the magnitude of this effect, we overexpressed ET A and ET B receptor cDNAs in OKP cells. As shown in Fig. 1 A, in pooled cells stably transfected with the neomycin resistance gene alone, 10
Ϫ8 M ET-1 had no effect on antiporter activity. In three clones selected for highest expression of ET A mRNA by Northern blot, ET-1 also failed to regulate Na/H antiporter activity. By contrast, in two clones selected for highest expression of ET B mRNA, 10 Ϫ8 M ET-1 increased Na/H antiporter activity significantly, by 26% in ET B Ϫ8 M ET-1. *P Ͻ 0.01 vs control; **P Ͻ 0.001 vs control. Neo-res: control, n ϭ 6, ET-1, n ϭ 7; ET A 5: control, n ϭ 6, ET-1, n ϭ 6; ET A 6: control, n ϭ 10, ET-1, n ϭ 10; ET A 9: control, n ϭ 6, ET-1, n ϭ 6; ET B 5: control, n ϭ 6, ET-1, n ϭ 6; ET B 6: control, n ϭ 9, ET-1, n ϭ 8. (B) A typical tracing of Na/H antiporter activity in ET B 6 cells. Na ϩ was added at 8 min.
strated. Thus, the small effect of ET-1 on Na/H antiporter activity in wild-type cells was mediated by a small unmeasurable number of receptors or was due to a promiscuous interaction with another receptor. It is possible that transfection or treatment with G-418 inhibited receptor activity. Fig. 1 B shows a typical tracing of Na/H antiporter activity in ET B 6 cells. In ET B 6 cells, 10 Ϫ10 M ET-1 increased Na/H antiporter activity by 10% (P Ͻ 0.09), and 10 Ϫ9 M ET-1 increased Na/H antiporter activity by 32% (P Ͻ 0.001). All further studies were performed with 10 Ϫ8 M ET-1 in ET B 6 cells. The above studies suggest that binding of ET-1 to ET B receptors activates NHE-3. To confirm this, we examined the effect of receptor blockade in ET B 6 cells. Fig. 2 A shows results with 10 Ϫ6 M FR-139137, an ET A -selective antagonist, and 10
Ϫ6
M PD145065, an antagonist of both ET A and ET B receptors (17) . ET-1 induced activation of the Na/H antiporter was inhibited by the nonselective antagonist but not by the ET Aselective antagonist, confirming an effect mediated by the ET B receptor. Fig. 2 B shows that BQ788, a selective ET B receptor blocker, completely inhibited ET-1-induced Na/H antiporter activation. Fig. 2 C shows that IRL-1620, a specific ET B receptor agonist (18), increased Na/H antiporter activity by 46%. Thus, all of these studies demonstrate that the effect of ET-1 is mediated by the ET B receptor.
In the above studies, Na/H antiporter activity was assayed 35 min after addition of ET-1. To determine the time course of the effect, 10 Ϫ8 M ET-1 was added at varying times before initiation of the assay (nigericin addition). At 5 min, ET-1 increased Na/H antiporter activity by 11% (NS; n ϭ 7, control; n ϭ 8, ET-1); at 12 min, ET-1 increased Na/H antiporter activity by 48% (P Ͻ 0.001; n ϭ 7); at 35 min, ET-1 increased Na/H antiporter activity by 40% (P Ͻ 0.001; n ϭ 8). Thus, endothelin achieves a maximal effect within 12 min.
Role of adenylyl cyclase and protein kinase A. Protein kinase A is a potent inhibitor of the proximal tubule apical membrane Na/H antiporter. A number of hormones are believed to regulate Na/H antiporter activity through regulation of adenylyl cyclase and secondarily of protein kinase A activity (4) . In ET B 6 cells, 10 Ϫ8 M ET-1 inhibited PTH-stimulated cAMP production by 28% (Fig. 3) . In the presence of PD145065, a nonselective endothelin receptor antagonist, 10 Ϫ8 M ET-1 did not significantly affect cAMP production (115Ϯ11 vs 96Ϯ10 pmol/mg protein per h, control vs ET-1, NS, n ϭ 9). In the presence of FR-139137, an ET A -selective antagonist, 10 Ϫ8 M ET-1 significantly inhibited cAMP production (117Ϯ11 vs 87Ϯ9 pmol/mg protein per h, P Ͻ 0.05, n ϭ 9). Thus, binding of ET-1 to ET B receptors inhibits adenylyl cyclase.
To determine the role of inhibition of adenylyl cyclase and protein kinase A in NHE-3 regulation, three studies were performed. Fig. 4 shows results of studies examining the effect of 10 Ϫ4 M 8-bromo cAMP on the response to ET-1. If ET-1 increases Na/H antiporter activity by inhibition of adenylyl cyclase, addition of excess exogenous cAMP should prevent this effect. ET-1 alone caused a 30% increase in Na/H antiporter Ϫ6 M PD145065, a nonselective endothelin receptor antagonist. *P Ͻ 0.001 vs control. FR-139137: vehicle, control, n ϭ 10, ET-1, n ϭ 10; inhibitor, control, n ϭ 10, ET-1, n ϭ 9; PD145065: vehicle, control, n ϭ 10, ET-1, n ϭ 10; inhibitor, control, n ϭ 10, ET-1, n ϭ 9. (B) Na/H antiporter activity (pH U/min) is plotted in the absence and presence of 10 Ϫ8 M ET-1, and in the absence and presence of 1.5 ϫ 10 Ϫ8 M BQ788, an ET B -selective receptor antagonist. *P Ͻ 0.05 vs control. Vehicle, control, n ϭ 3, ET-1, n ϭ 5, Inhibitor, control, n ϭ 4, ET-1, n ϭ 5. (C) Na/H antiporter activity is plotted in the absence and presence of 10 Ϫ8 M IRL-1620, a selective ET B receptor agonist. *P Ͻ 0.005, n ϭ 7.
activity, and 8-bromo cAMP alone caused a 22% decrease in Na/H antiporter activity. In the presence of 8-bromo cAMP, ET-1 caused an increase in Na/H antiporter activity equal to 49% of the increase seen in the absence of 8-bromo cAMP. The observation that endothelin can activate the Na/H antiporter in the presence of exogenous cAMP demonstrates that regulatory mechanisms exist independently of adenylyl cyclase inhibition. The observation that the endothelin-induced increase in antiporter activity was smaller in magnitude in the presence of exogenous cAMP suggests that part of the stimulatory effect is mediated by inhibition of adenylyl cyclase. However, other explanations exist (see Discussion).
To address this further, we examined the effect of 30 M H89, a protein kinase A inhibitor (19) . As shown in Fig. 5, H89 did not inhibit ET-1-induced increases in Na/H antiporter activity. In the absence of H89, ET-1 increased Na/H antiporter activity by 0.52 pH U/min (41% increase), and in the presence of H89 ET-1 increased Na/H antiporter activity by 0.53 pH U/min (54% increase). To confirm that H89 inhibited regulation of the Na/H antiporter by protein kinase A in these cells, we examined the effect of H89 on forskolin-induced Na/H antiporter inhibition. 10 Ϫ5 M forskolin inhibited Na/H antiporter activity by 30% (n ϭ 8, P Ͻ 0.005). This effect was blocked by 5 M H89 (forskolin caused a 7% inhibition; n ϭ 4, NS), and by 10 M H89 (forskolin caused an 11% increase; n ϭ 4, NS).
These results suggest that ET-1-induced inhibition of adenylyl cyclase does not contribute to the increase in Na/H antiporter activity. In agreement with this, H7, which inhibits protein kinase A and protein kinase C (19), did not inhibit endothelininduced Na/H antiporter activation (see below).
To confirm these results further, we examined the effect of pertussis toxin pretreatment on ET-1-induced Na/H antiporter activation. Hormone-mediated adenylyl cyclase inhibition is frequently mediated by pertussis toxin-sensitive G proteins. Pretreatment of ET B 6 cells with 200 ng/ml pertussis toxin for 4 h inhibited ET-1-induced inhibition of cAMP accumulation. However, this maneuver did not inhibit ET-1-induced increases in Na/H antiporter activity. As shown in Fig. 6 A, 10 
Ϫ8
M ET-1 increased Na/H antiporter activity by 40% in vehiclepretreated and in pertussis toxin-pretreated cells. Pertussis toxin pretreatment of cells ADP ribosylated all potential G protein substrates, as evidenced by the observation that pretreatment of cells inhibited subsequent in vitro pertussis toxininduced ADP ribosylation of 41-kD proteins (Fig. 6 B) . Once again, these results suggest that ET-1-induced increases in Na/H antiporter activity are not dependent on adenylyl cyclase inhibition.
Role of cell calcium and protein kinase C. Endothelin has been shown to activate phospholipase C, secondarily leading to increases in [Ca 2ϩ ] i and activation of protein kinase C (20) . We therefore examined the role of these pathways in Na/H antiporter activation. As shown in Fig. 7 A, ] i increased from 106Ϯ9 nM to 263Ϯ14 nM at ‫ف‬ 15 s and then decreased to a plateau of 133Ϯ9 nM (n ϭ 3). Fig. 7 ] i , whereas FR-139137, the ET A -selective antagonist, had no effect (Table II) .
To further characterize the mechanism of the ET-1 induced increase in [Ca 2ϩ ] i , a number of studies were performed (Table  III) . Pretreatment of cells with 200 ng/ml pertussis toxin for 4 h decreased and slowed but did not eliminate the peak Ca 2ϩ response ( Fig. 8 A, Table III ). Removal of extracellular Ca 2ϩ did not prevent the peak increase in [Ca 2ϩ ] i but prevented the sustained increase (Fig. 8 B, Table III ). Treatment with exoge- ] i 108Ϯ2 nM; n ϭ 5). As shown in Fig. 9 , prevention of [Ca 2ϩ ] i increases with BAPTA-inhibited ET-1-induced Na/H antiporter activation by 57%. In the absence of BAPTA, ET-1 increased Na/H antiporter activity by 49%, whereas, in the presence of BAPTA, ET-1 increased Na/H antiporter activity by only 21%. Thus, ET-1 binding to ET B receptors increases [Ca 2ϩ ] i , which mediates in part Na/H antiporter activation. Increases in [Ca 2ϩ ] i can activate CaM-dependent kinase (CaM kinase). To determine if CaM kinase mediates Na/H antiporter activation, cells were treated with 40 M KN62, an inhibitor of this kinase (19) . In the absence of KN62, ET-1 increased Na/H antiporter activity by 39%, whereas, in the presence of KN62, ET-1 increased Na/H antiporter activity by only 19% (51% inhibition; Fig. 10 ).
Binding of ET to the ET B receptor has been demonstrated to activate nitric oxide (NO) synthase, a process in which CaM kinase and tyrosine kinase pathways may play a role (21) . To examine whether NO plays a role in ET-1-induced Na/H antiporter activation, cells were treated with 2 mM N-nitro-l-arginine (l-NA), an NO synthase inhibitor (22, 23) . In the absence of l-NA, ET-1 increased Na/H antiporter activity by 34% (Fig.  11) . l-NA caused a 46% decrease in baseline Na/H antiporter rate, but did not inhibit the effect of ET-1, which increased Na/H antiporter activity by 93% (Fig. 11) . Activation of phospholipase C can also lead to protein kinase C activation. To address whether protein kinase C plays a role in Na/H antiporter activation, cells were treated with 40 M H7, an inhibitor of protein kinases A and C (19) . This concentration of H7 completely inhibits phorbol ester-induced increases in c-fos mRNA abundance in OKP cells (24) . However, H7 had no effect on ET-1-induced increases in Na/H antiporter activity (Fig. 12) .
ET A receptors have been found to increase cell [Ca 2ϩ ] in many cell types (20) . To examine whether increases in [Ca 2ϩ ] i were sufficient to increase Na/H antiporter activity, we examined [Ca 2ϩ ] i in ET A 6 cells. These cells had the highest levels of expression of ET A mRNA but did not demonstrate an increase in Na/H antiporter activity in response to 10 Ϫ8 M ET-1 ( Fig.  1 A) . ET-1 caused an increase in [Ca 2ϩ ] i in ET A 6 cells that was similar to that seen with ET B 6 cells (Table IV) . ET-1 had no effect on [Ca 2ϩ ] i in pooled neomycin-resistant cells (Table IV) . Thus, whereas increases in [Ca 2ϩ ] i are required for 50% of ET-1-induced Na/H antiporter stimulation, they are not sufficient.
Role of other signaling pathways. To examine if icosanoids play a role, the effects of indomethacin (cyclooxygenase inhibitor) and nordihydroguaiaretic (NDGA, a lipoxygenase and cytochrome P450 inhibitor) were examined (Table V) . In the absence of indomethacin, ET-1 increased Na/H antiporter activity by 42%, whereas, in the presence of 20 M indomethacin, ET-1 increased Na/H antiporter activity by 42%. In the absence of NDGA, ET-1 increased Na/H antiporter activity by 40%, whereas, in the presence of 10 M NDGA, ET-1 increased Na/H antiporter activity by 48%.
Lastly, we examined whether protein kinase G played a role by examining the effect of 8-bromo cGMP. ET-1 increased Na/H antiporter activity by 43% (P Ͻ 0.001). 10 Ϫ4 M 8-bromo cGMP had no effect on Na/H antiporter activity, and, in the presence of 8-bromo cGMP, ET-1 increased Na/H anti- 
Discussion
Previous studies have demonstrated that ET-1 increases Na/H antiporter activity in mesangial cells and Chinese hamster ovarian-K1 cells overexpressing endothelin receptors (25, 26) . These cells express the ubiquitous Na/H antiporter isoform, NHE-1. The present studies demonstrate that ET-1 increases Na/H antiporter activity in OKP cells. This Na/H antiporter is encoded by the NHE-3 isoform (9), the isoform which encodes the apical membrane Na/H antiporter of the renal proximal tubule and thick ascending limb (5, 6) . Overexpression of ET B receptors significantly increased the response to endothelin, whereas overexpression of ET A receptors was without effect. These results are not due to a failure of ET A -transfected cells to express functional receptor, in that ET A 6 cells demonstrated an increase in [Ca 2ϩ ] i in response to ET-1. Pooled neomycin-resistant cells demonstrated no increase in [Ca 2ϩ ] i . A role for the ET B receptor was confirmed by the demonstration that ET-1-induced increases in Na/H antiporter activity were not blocked by an ET A -selective endothelin receptor antagonist but were blocked by a nonselective ET A and ET B receptor antagonist and an ET B -selective receptor antagonist. In addition, IRL-1620, a selective ET B receptor agonist, increased Na/ H antiporter activity in these cells.
Investigators have been unable to demonstrate significant expression of ET A or ET B receptor mRNA in the proximal tubule using reverse transcriptase-PCR (27) . However, endothelin binds to S1 proximal tubule cells, with ET-1 and ET-3 binding of similar magnitude, consistent with the presence of ET B receptors (28) . Whereas ET-1 and ET-2 interact with ET A and ET B receptors, ET-3 interacts with high affinity only with ET B receptors (1, 2) . Thus, ET-3 can serve as a selective activator of ET B receptors. Parallel roles for ET-3 and ET B receptors are suggested by the observation that genetic disruption of the ET-3 and ET B genes leads to similar phenotypes (29, 30). The proximal tubule expresses significant amounts of ET-3 mRNA, raising the possibility that ET-3 could function as an autocrine factor (31) . ET-1 is also expressed in the proximal tubule, but in lesser amounts (32) .
In ET B 6 cells, ET-1 caused a spike increase followed by a sustained increase in [Ca 2ϩ ] i . This finding agrees with previous results in many cell types, which have found that ET A and ET B receptors activate phospholipase C, leading to increases in inositol-1,4,5-trisphosphate and [Ca 2ϩ ] i (20, 33) . The mechanism of the increase in [Ca 2ϩ ] i is similar to that seen with many G protein-coupled receptors. Ligand binding to receptor activates phospholipase C through pertussis toxin-sensitive and -insensitive G protein pathways. The pertussis toxin-insensitive G protein is likely G ␣q or a related G protein (G ␣11 , G ␣14 , and G␣16) (34) . Pertussis toxin-sensitive increases in [Ca 2ϩ ] i may be due to G ␣i or G ␤␥ (34 ] i but did not increase Na/H antiporter activity. In the proximal tubule, increases in [Ca 2ϩ ] i have been proposed to stimulate and inhibit Na and H trans- Figure 11 . l-NA does not inhibit ET-1-induced Na/H antiporter activation. The effect of 10 Ϫ8 M ET-1 on Na/H antiporter activity (pH U/ min) was compared in the absence and presence of 2 mM l-NA. *P Ͻ 0.05 vs no ET-1, **P Ͻ 0.001 vs no ET-1. Control, n ϭ 8; ET-1, n ϭ 8; l-NA, n ϭ 8; l-NA ϩ ET-1, n ϭ 9. Figure 12 . H7 does not inhibit ET-1-induced Na/H antiporter stimulation. The effect of 10 Ϫ8 M ET-1 on Na/H antiporter activity (pH U/ min) was examined in ET B 6 cells in the absence and presence of 40 M H7. *P Ͻ 0.001 vs no ET-1. Control, n ϭ 9; ET-1, n ϭ 9; H7, n ϭ 8; H7 ϩ ET-1, n ϭ 9. port (35) (36) (37) . Studies in renal cortical apical membranes have suggested that CaM kinase directly inhibits the Na/H antiporter (38) . Thus, the effect of increases in [Ca 2ϩ ] i and CaM kinase on the Na/H antiporter are likely complex, depending on many possible variables, including activation of parallel pathways, subcellular localization of Ca , and other yet to be defined factors.
Although phospholipase C activation would also be expected to increase diacylglycerol levels and activate protein kinase C, inhibition of protein kinase C with H7 had no effect on activation of the Na/H antiporter by ET-1. This result is different from that of Walter et al., who found that calphostin C inhibited ET-1-induced increases in Na/H antiporter activity in OK cells (39) . The reason for this discrepancy is not clear, but it may relate to differences in the cells used. The present studies also found no role for protein kinase G, cyclooxygenase, lipoxygenase, or cytochrome P450 pathways.
The present studies confirm that ET-1 binding to ET B receptors causes inhibition of adenylyl cyclase activity, as found previously (8, 40) . Also in agreement, addition of ET-1 to ET B overexpressing Chinese hamster ovarian cells inhibits adenylyl cyclase, whereas addition to ET A -overexpressing cells stimulates adenylyl cyclase (33) . However, regulation of adenylyl cyclase likely does not mediate regulation of NHE-3, in that H89 and H7, inhibitors of protein kinase A (19), did not inhibit the endothelin-induced increase in Na/H antiporter activity. To prove that H89 inhibited protein kinase A in these cells, we showed that H89 blocked forskolin-induced Na/H antiporter inhibition. Lastly, we showed that pertussis toxin pretreatment, which inhibits ET-1-induced inhibition of adenylyl cyclase, did not inhibit Na/H antiporter activation. The observation that exogenous 8-bromo cAMP addition partially inhibited endothelin-induced Na/H antiporter activation may be attributable to regulation of an endothelin-signaling pathway by protein kinase A, or may be due to the fact that protein kinase A is a potent inhibitor of Na/H antiporter activity and thus prevents activation by other agonists. We have previously found that exogenous 8-bromo cAMP inhibited angiotensin II-induced Na/H antiporter stimulation in OKP cells, in spite of the fact that angiotensin II had no effect on cAMP production in these cells (41) .
In the in vitro-perfused proximal straight tubule, low concentrations of endothelin stimulate volume absorption whereas high concentrations inhibit volume absorption (3). ET-1 has been demonstrated to increase proximal tubule apical membrane Na/H antiporter activity (7, 8) . The present studies demonstrate that ET binding to ET B receptors leads to an increase in NHE-3 activity. Thus, stimuli that increase renal production of ET-1 or ET-3 could secondarily increase Na/H antiporter activity, which would lead to an increase in renal sodium reabsorption. Endothelin-induced increases in [Ca 2ϩ ] i mediate 50% of the increase in Na/H antiporter activity. In recent studies we have found that herbimycin A and tyrphostin A47, tyrosine kinase inhibitors, also prevent 50% of ET-1-induced Na/H antiporter activation (unpublished observation). Herbimycin A and BAPTA together completely prevent antiporter activation. In the present studies we found that herbimycin A does not inhibit ET-1-induced increases in cell [Ca 2ϩ ]. Thus, Ca 2ϩ -dependent and tyrosine kinase pathways function in parallel, and each mediates 50% of endothelin-induced Na/H antiporter stimulation. 
